According to existing research, the vaccines create enough antibodies to fight the disease
NEW YORK – New York Blood Center (NYBC) has published an analysis in Science Magazine that points to the vaccines’ efficacy against mutated strains of COVID-19. While the mutated strains of COVID-19 are concerning, NYBC found that existing research indicates all three vaccines authorized for use by the FDA–Pfizer, Johnson & Johnson, and Moderna–create enough antibodies to fight the virus variants. The article “Vaccine efficacy probable against COVID-19 variants” by Dr. Christopher D. Hillyer and Dr. Larry Luchsinger is available on the journal’s website, here.
“Our analysis finds that there is more than enough evidence to support that the vaccines will work against mutated forms of COVID-19,” said Larry Luchsinger, Assistant Member, Lindsley F. Kimball Research Institute of the New York Blood Center. “It has been incredible to see the science community come together and create these three vaccines in just under a year’s time. Given the increasing number of vaccinations each day and their effectiveness against COVID-19, we are very hopeful that the pandemic will soon be behind us.”
In addition to this research, NYBC is developing two novel SARS-CoV-2 vaccine candidates that are currently in pre-clinical studies, conducting vaccines trials, and investigating biomarkers that may determine individuals at risk for severe disease. NYBC also maintains the nation’s largest public bank of COVID-19 convalescent plasma, which it can be accessed for research. To support NYBC’s COVID-19 research, visit nybc.org/fightcovid